Blockage of store-operated Ca\textsuperscript{2+} entry antagonizes Epstein–Barr virus-promoted angiogenesis by inhibiting Ca\textsuperscript{2+} signaling-regulated VEGF production in nasopharyngeal carcinoma

Jiaxiang Ye\textsuperscript{1} Junqi Huang\textsuperscript{2} Qian He\textsuperscript{3} Weilin Zhao\textsuperscript{4} Xiaoying Zhou\textsuperscript{5} Zhe Zhang\textsuperscript{4} Yongjiang Li\textsuperscript{1} Jiazhang Wei\textsuperscript{6} Jinyan Zhang\textsuperscript{1}

\textsuperscript{1}Department of Medical Oncology, Affiliated Cancer Hospital of Guangxi Medical University, Nanning 530021, People’s Republic of China; \textsuperscript{2}Department of Pathology, Affiliated Cancer Hospital of Guangxi Medical University, Nanning 530021, People’s Republic of China; \textsuperscript{3}Department of Otorhinolaryngology and Head and Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, People’s Republic of China; \textsuperscript{4}Department of Pathology, Affiliated Cancer Hospital of Guangxi Medical University, Nanning 530021, People’s Republic of China; \textsuperscript{5}Department of Otorhinolaryngology and Head and Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, People’s Republic of China; \textsuperscript{6}Department of Otolaryngology and Head and Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, People’s Republic of China.

Background: Epstein–Barr virus (EBV) actively contributes to the pathological process of nasopharyngeal carcinoma (NPC) by enabling NPC cells to acquire various capacities required for their malignant biological actions. Our earlier works demonstrated that EBV-encoded latent membrane protein 1 (LMP1) enhanced vascular endothelial growth factor (VEGF)-mediated angiogenesis by boosting store-operated Ca\textsuperscript{2+} entry (SOCE) upon extracellular epidermal growth factor (EGF) stimulation. However, the antagonistic effects of SOCE blockage on EBV-promoted angiogenesis must be appropriately evaluated in vivo, and the global effect of EBV infection on the EGF-elicited cytosolic Ca\textsuperscript{2+} signaling, which regulates VEGF-mediated angiogenesis remains to be further clarified.

Materials and methods: Two EBV-infected NPC cell lines, CNE2-EBV and HK1-EBV, along with their parental cell lines were employed in the present study. Dynamic cytosolic Ca\textsuperscript{2+} changes were measured in individual fluorescent Ca\textsuperscript{2+} indicator-loaded cells. Amounts of VEGF production were determined by enzyme-linked immunosorbent assay (ELISA). Human umbilical vein endothelial cells (HUVECs)-formed tube networks were quantitatively evaluated as an in vitro angiogenesis assay. A mouse model concurrently bearing EBV-positive/negative xenografts was utilized to evaluate the tumor growth and angiogenesis in vivo.

Results: EBV infection reliably promoted transplanted tumor growth while enhancing angiogenesis. Introduction of EBV into EBV-negative NPC cells increased the EGF-stimulated VEGF production while amplifying the EGF-evoked Ca\textsuperscript{2+} responses. Inhibition of the EBV-boosted Ca\textsuperscript{2+} signaling using 2-aminoethyl diphenylborinate (2-APB), a specific SOCE inhibitor, effectively antagonized the EBV-promoted VEGF production and endothelial tube formation in vitro. Pharmacological blockage of SOCE exhibited anti-angiogenic effect in the EBV-positive xenografts.

Conclusion: SOCE can serve as a candidate pharmacological target for treating NPC, as blockage of the Ca\textsuperscript{2+} signaling via SOCE is a feasible strategy to suppress the EBV-driven malignant profiles in NPC cells.

Keywords: nasopharyngeal carcinoma, store-operated Ca\textsuperscript{2+} entry, angiogenesis, Epstein–Barr virus, vascular endothelial growth factor

Introduction

Nasopharyngeal carcinoma (NPC) is a distinctive human head-and-neck malignant disease, with an unbalanced geographical and ethnic distribution, high sensitivity to both radiotherapy and chemotherapy, but a strong tendency to spread to regional lymph nodes and distant secondary organs.\textsuperscript{1,2} The pathogenetic causes for NPC development are diverse and complex, among which latent Epstein–Barr virus (EBV) infection has...
been established as being responsible for various malignant biological behaviors of NPC cells.\(^3\,^4\) Latent membrane proteins (LMPs) encoded by EBV, including LMP1 and LMP2A, act as two functional oncogenic proteins that drive the progressive evolution of NPC.\(^5\,^6\)

Previously, we reported that inhibition of store-operated Ca\(^{2+}\) entry (SOCE) suppressed epidermal growth factor (EGF)-stimulated cell migration and eliminated the extravasation event from the vasculature in NPC cells.\(^7\) In our later work, we found that LMP1 promoted cell migration and VEGF-mediated angiogenesis by boosting EGF-evoked SOCE, while blocking SOCE effectively blunted the LMP1-enhanced malignant capacities.\(^8\) These findings suggest that blockage of the oncogenic signal transduction from an exterior space into the cytoplasm through SOCE-mediated Ca\(^{2+}\) influx can serve as an alternative means to antagonize the EBV-promoted malignant profiles. Our recent study showed that a widely used pharmacological blocker of Ca\(^{2+}\) release-activated Ca\(^{2+}\) entry, SKF95365, inhibited colony formation and induced apoptosis and cell cycle arrest at the G2/M and S phases in NPC cells.\(^9\) However, within the dose range in which SKF95365 showed obvious inhibitory effects on SOCE, it also increased the apparent Ca\(^{2+}\) release from intracellular Ca\(^{2+}\) stores and induced significantly increased cell motility,\(^9\) indicating that SKF95365 lacks the essential property of selectivity to serve as an SOCE inhibitor for antitumor agents, which may lead to unexpected off-target effects.

In the present study, we aimed to develop a mouse model concurrently bearing EBV-positive/negative xenografts, enabling us to logically evaluate candidate antitumor drugs targeting EBV-driven malignant profiles for NPC treatment in vivo. We further provide an experimental paradigm by validating the effects of blockage of SOCE using a selective pharmacological inhibitor, 2-aminoethyl diphenylborinate (2-APB), on tumor-related angiogenesis, which is driven by EBV infection in NPC.\(^3\,^6\)

**Materials and methods**

**Cell culture**

The study was approved by the ethics committee of Guangxi Medical University. Human NPC cell lines CNE2 and HK1 (both are EBV-negative) were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 5% fetal bovine serum (FBS), penicillin at 100 U/mL, and streptomycin at 100 μg/mL (Thermo Fisher Scientific, Waltham, MA, USA). The cells were routinely maintained in an incubator at 37°C under 5% CO\(_2\) and 100% humidity. CNE2-EBV cells were kindly provided by Prof Musheng Zeng’s group (Sun Yat-sen University Cancer Center, China), and HK1-EBV cells were kindly gifted by Prof Sai-Wah Tsao (Hong Kong University, China). CNE2-EBV and HK1-EBV cells were established as described previously.\(^10\) Briefly, the NPC cells were cocultured with enhanced green fluorescent protein (EGFP)-tagged neo/EBV-infected Akata cells that constantly produce infectious recombinant EBV (rEBV). Then, the NPC cells were incubated in the medium containing G418 for EBV-positive cell selection for 2 weeks.\(^11\) Human umbilical vein endothelial cells (HUVECs; CRL-1730\(^\text{TM}\); American Type Culture Collection [ATCC]; Manassas, VA, USA) were cultured in Ham’s F-12K Medium (Thermo Fisher Scientific, Waltham, MA, USA,) supplemented with 10% FBS, heparin at 0.1 mg/mL, and antibiotics.

**Measurement of change in cytosolic Ca\(^{2+}\) ([Ca\(^{2+}\)]\(_{\text{cyt}}\)**

The cells were preincubated in serum-free medium for 24 hours before measuring cytosolic Ca\(^{2+}\) to avoid any unexpected stimuli inducing Ca\(^{2+}\) responses. Cytosolic Ca\(^{2+}\) concentration ([Ca\(^{2+}\)]\(_{\text{cyt}}\)) was measured in individual serum-deprived cells over a time course using a membrane-permeable fluorescent Ca\(^{2+}\) indicator, namely, the acetoxy-methyl ester of fura-2 (fura-2-AM) (Dojindo Molecular Technologies, Inc, Kumamoto, Japan), as described in our previous studies.\(^7\,^9\,^12\)

**Drug and solution**

2-APB was purchased from Sigma-Aldrich Co., (St Louis, MO, USA). To avoid any bias resulting from different amounts of DMSO, 2-APB was predissolved in DMSO at various concentrations as stock solutions, which were further added into the medium or PBS (1:1000 dilution) before the experiments, with pH 7.4 at 25°C. Therefore, the amounts of DMSO added into each dosage group were equal. Additionally, an equal amount of DMSO was added into the medium or PBS as a vehicle control, if necessary.

**Immunoblotting**

EBV-encoded LMP1 expression was detected using western blot analysis (anti-LMP1 antibody, 1:200 dilution; Abcam Corp, Cambridge, UK), according to the standard protocol. α-Tubulin expression was examined as an internal control (anti-alpha-tubulin antibody, 1:500 dilution; Abcam Corp). For the assay, each lane was loaded with 50 μg of protein. The blots were visualized using enhanced chemiluminescence detection (Pierce, Rockford, IL, USA).
VEGF production and in vitro angiogenesis assay

A total of 5×10^5 NPC cells suspended in medium was seeded into each well of a six-well plate and allowed to grow until an ~85% confluent monolayer was obtained. The cells were preincubated with serum-free medium for 24 hours. Medium containing EGF at 50 ng/mL and 0.25% serum was applied to stimulate VEGF release by the serum-starved NPC cells for 12 hours. The amount of VEGF production in the conditioned medium was examined using an enzyme-linked immunosorbent assay (ELISA) kit, according to the manufacturer's protocol (VEGF Human ELISA Kit; Thermo Fisher Scientific, Waltham, MA, USA). The conditioned medium was harvested for a subsequent in vitro angiogenesis assay utilizing the μ-Plate Angiogenesis 96-well kit (Ibidi GmbH, Martinsried, Germany), as described in previous studies.13 In brief, HUVECs were seeded onto a Matrigel-pretreated surface and allowed to form new vessels with incubation in the cell-conditioned medium. The total tube length in each well was measured to quantitatively evaluate the VEGF-mediated angiogenesis using WimTube Image Analysis (Ibidi GmbH).

Nude mouse xenograft

All of the in vivo experiments performed in our study conformed to the Guide for the Care and Use of Laboratory Animals.14 All experiments were performed in accordance with the regulations of the Animal Research Committee of Guangxi Medical University. All the experiments were approved by the Animal Research Committee of Guangxi Medical University. The bilateral dorsal sites of female BALB/c(nu/nu) mice, aged 6–8 weeks, were subcutaneously inoculated with 5×10^4 EBV-negative (mock control, right side) and EBV-infected CNE2 cells (left side). Five or seven mice were assigned to each experimental group, as indicated. Palpable xenografts could be observed 10 days after the inoculations. The tumor dimensions were measured every 5 days using a vernier caliper, and the xenograft volumes were calculated according to the formula \( V = (W^2 \times L)/2 \), where \( W \) was the width and \( L \) was the length. At the end of the xenograft growth observation, the mice were anesthetized and perfused with PBS with 4% paraformaldehyde; then, the mice were sacrificed and the transplanted tumors were isolated. The tumor tissues were subjected to routine paraffin-embedded sectioning followed by immunohistochemical analysis of angiogenesis. A well-known vascular endothelial marker, platelet endothelial cell adhesion molecule-1, PECAM-1/CD31, was detected to estimate angiogenesis within the xenografts.

Results

EBV infection accelerates xenograft growth by promoting tumor-related angiogenesis

The protocol of establishing of a mouse model bearing both EBV-positive and EBV-negative xenografts is briefly illustrated (Figure 1A). A sequence encoding EGFP was simultaneously introduced into the CNE2 and HK1 cells accompanied with the in vitro EBV infection, as described previously.10,11 The EGFP thus served as a visible tag enabling dynamic and real-time monitoring of the EBV infection (Figure 1B). To further validate the effectiveness of the EBV infection, immunoblotting was performed to detect the expression of a well-characterized oncoprotein that is encoded by EBV, namely, LMP1, in CNE2-EBV and HK1-EBV cells after 2 weeks of cell selection with Geneticin antibiotic treatment (Figure 1C). The tumor-associated neovasculature is crucial for tumor growth, as it supplies the proliferative cancer cells with abundant oxygen and nutrients and allows for the evacuation of metabolic waste. To evaluate the effects of EBV infection on tumor-associated angiogenesis and NPC tumor growth, EBV-positive and EBV-negative CNE2 cells were inoculated at bilateral dorsal sites, whereby EBV-positive cells were implanted on the left and EBV-negative cells on the right (Figure 1D). The EBV-positive xenografts grew faster compared with the EBV-negative xenografts (Figure 1E and F). In addition, by performing immunohistochemical analysis, we demonstrated that the neovasculature within the transplanted tumors was significantly enhanced in the EBV-positive xenografts (Figure 1G and H), reflecting the well-known fact that EBV infection promotes tumor-associated angiogenesis.3–6 The mouse model established here reliably showed enhanced tumor-associated angiogenesis and tumor growth promoted by EBV, thus enabling the subsequent in vivo antitumor drug screening and efficacy validation in NPC.

EBV infection increases EGF-stimulated VEGF production and enhances endothelial tube formation

Cancer cell-released VEGF is a key exocrine molecule that mobilizes the surrounding endothelial cells to form the endothelium for vascularization. Therefore, we further determined VEGF production in the EBV-infected CNE2 and
HK1 cells. The amounts of spontaneous VEGF production were not significantly different between the EBV-positive and EBV-negative cells. However, VEGF production in the EBV-infected cells in the presence of external EGF stimulation was significantly increased (Figure 2A). To further elucidate the effect of EBV infection on VEGF-mediated angiogenesis, an endothelial tube formation assay was used. The in vitro angiogenesis assay showed that EBV infection promoted endothelial tube formation significantly in the presence of EGF stimulation (Figure 2B).
EBV infection promotes EGF-evoked Ca\(^{2+}\) influx via SOCE

It is well established that the VEGF produced and released by cancer cells can be manipulated by Ca\(^{2+}\) signaling.\(^{15,16}\) In our previous study, we showed that EBV-encoded LMP1 augmented VEGF production by boosting the Ca\(^{2+}\) responses via SOCE.\(^8\) However, the global effects of EBV infection on cytosolic Ca\(^{2+}\) signaling, which implicated VEGF production, still remain unclear. In the present study, we tested the Ca\(^{2+}\) responses in two EBV-infected NPC cell lines, CNE2-EBV and HK1-EBV cells, compared to their mock controls. EBV infection significantly boosted the immediate cytosolic Ca\(^{2+}\) elevation found upon external EGF stimulation (Figure 3A). According to a standard protocol for characterizing SOCE, we confirmed that EBV promoted the Ca\(^{2+}\) responses by boosting the Ca\(^{2+}\) influx via the plasma membrane Ca\(^{2+}\) channels but had no obvious effect on the Ca\(^{2+}\) release from the intracellular Ca\(^{2+}\) store, namely, the endoplasmic reticulum (ER) (Figure 3B). Thus, EBV infection promotes tumor-associated angiogenesis by amplifying the Ca\(^{2+}\) signaling via SOCE, which regulates VEGF production.

2-APB blunts the EBV-promoted VEGF production and endothelial tube formation while inhibiting EGF-activated SOCE

2-APB was initially recognized as a membrane-permeable modulator of intracellular inositol triphosphate (IP3)-induced Ca\(^{2+}\) release.\(^{17}\) However, later studies have demonstrated that the main pharmacological antagonistic effect of 2-APB is on SOCE, rather than on IP3-induced Ca\(^{2+}\) release.\(^{18}\) In this study, 2-APB at 5 μmol/L slightly inhibited the EGF-stimulated transient Ca\(^{2+}\) increases, while at 20 μmol/L, 2-APB exhibited obvious inhibitory effects (Figure 4A). Because 2-APB can not only inhibit SOCE but may also affect the ER-released Ca\(^{2+}\) and because this pharmacological property varies in different cell types,\(^{17,19}\) we determined the effects of 2-APB on ER-released Ca\(^{2+}\)) and the following activated SOCE. 2-APB showed no obvious effect on intracellular Ca\(^{2+}\) release but obviously inhibited the Ca\(^{2+}\) influx via SOCE in CNE2-EBV cells (Figure 4B). Similarly, 2-APB did not significantly affect the peak of the ER-released Ca\(^{2+}\) and only slightly influenced the duration of Ca\(^{2+}\) elevation in HK1-EBV cells while almost
blocking the subsequent Ca\(^{2+}\) influx via SOCE (Figure 4B). As expected, 2-APB at 5 μmol/L mildly affected the EGF-stimulated VEGF production in both the EBV-infected CNE2 and HK1 cells, and 2-APB at 20 μmol/L obviously reduced the amount of VEGF (Figure 4C). Moreover, 2-APB at 20 μmol/L suppressed the VEGF-driven endothelial tube formation (Figure 4D), which was shown to be promoted by EBV infection in the present study (Figure 2B).

2-APB antagonizes EBV-positive xenograft growth by inhibiting EBV-promoted angiogenesis

We further examined the effects of 2-APB on transplanted NPC tumor growth in the xenograft-bearing mouse model described earlier (Figure 5A). Intraperitoneal injection of 2-APB into the mice harboring NPC xenografts resulted in a reduction in the EBV-positive tumor growth, determined by the measured volumes and weights of the xenografts (Figure 5B–D). Furthermore, 2-APB also effectively inhibited EBV-promoted angiogenesis, as determined by the intratumor vessel number detected through the immunohistochemical analysis of the xenograft sections (Figure 5E). 2-APB also mildly decreased the EBV-negative xenograft growth (Figure 5D).

**Discussion**

EBV latent infection has been established as a key pathogenic factor for the progression of EBV-associated malignant diseases, such as Burkitt’s lymphoma, Hodgkin’s lymphoma, some natural killer (NK)/T-cell lymphomas, posttransplant lymphoproliferative disease, and NPC.\(^3\) EBV-encoded oncofunctional molecules, such as the LMPs LMP1 and LMP2A, enable NPC cells to acquire various malignant phenotypes required for tumorigenesis.\(^4,5\) EBV-encoded LMP1 plays an integral part during NPC pathogenesis.\(^6\) LMP1 exerts oncogenic properties by inducing various phenotypic alterations in NPC cells, including resistance to apoptosis, modulation of epithelial–mesenchymal transition (EMT), as well as promotion of migration, invasion, and angiogenesis.\(^6\) In our previous study, we demonstrated that LMP1 enhanced VEGF production by amplifying the external EGF-evoked Ca\(^{2+}\) signaling via SOCE.\(^8\) Thus, blockage of EBV-manipulated Ca\(^{2+}\) signaling might serve
2-APB blunts EBV-promoted angiogenesis in NPC

As a potential therapeutic strategy for treating NPC, in our recent work, we reported that SKF96365, an inhibitor of the store-operated Ca\(^{2+}\) channel, inhibited colony formation and induced apoptosis and cell cycle arrest in NPC cells.\(^9\) However, SKF96365 also affected cytosolic Ca\(^{2+}\) signaling by directly inducing ER-released Ca\(^{2+}\), which was presumably responsible for the increased cell mortality.\(^9\) These results indicated that SKF96365 is not suitable for evaluating the effects of pharmacological blockage of SOCE on EBV-driven malignant profiles, such as migration, invasion, and angiogenesis, due to its toxic off-target effects. In the present study, we further tested the possibility that pharmacological blockage of SOCE using 2-APB, which was confirmed to have no obvious inhibitory effect on NPC cell proliferation in our previous study,\(^7\) could affect EBV-promoted angiogenesis in vitro and in vivo.

In this study, we showed that infection by EBV in two EBV-negative NPC cell lines, CNE2 and HK1, amplified

Figure 4 2-APB blunts EBV-promoted endothelial tube formation mediated by VEGF.

Notes: (A) Effects of 2-APB at increasing concentrations on EGF-evoked Ca\(^{2+}\) responses are shown. (B) Effects of 2-APB at 20 \(\mu\)mol/L on EGF-induced Ca\(^{2+}\) release from the ER and the following SOCE were measured in the absence and presence of extracellular Ca\(^{2+}\), successively. (C) Effects of 2-APB at various concentrations on VEGF-A production upon EGF stimulation were determined by ELISA. (D) Effects of 2-APB on endothelial tube formation are shown; scale bar = 100 \(\mu\)m. The data are representative of three independent experiments and are presented as the mean ± SEM (*\(P<0.05\), Student’s t-test).

Abbreviations: 2-APB, 2-aminoethyl diphenylborinate; EBV, Epstein–Barr virus; EGF, epidermal growth factor; ELISA, enzyme-linked immunosorbent assay; ER, endoplasmic reticulum; SOCE, store-operated Ca\(^{2+}\) entry.
the extracellular EGF-evoked Ca²⁺ influx via SOCE (Figure 3B). It is well-characterized that EBV-encoded LMPs profoundly remodel EGFR activation-launched signaling by functionalizing EGFR. Our earlier findings indicated that EBV-encoded LMP1 aggrandized EGF-stimulated Ca²⁺ signaling by enhancing Orai1 expression, a key component of membrane Ca²⁺ channels for SOCE. However, the solo ectopic expression of LMP1 might not completely reflect the entire picture of EBV infection on NPC cells, as proposed in our previous study. To achieve a full view of how EBV affects SOCE-mediated Ca²⁺ signaling, two EBV-infected NPC cell lines were used, which were generated by in vitro cell-to-cell cross-infection. Compared with the mock controls, the EBV-infected NPC cells showed amplified Ca²⁺ responses upon external EGF stimulation (Figure 3A), which was consistent with the results from LMP1-expressing cells in our earlier work.

VEGF is a crucial mediator for tumor-associated angiogenesis. Cancer cells utilize VEGF to mobilize the surrounding endothelial cells expressing VEGFR to construct a continuous endothelium, which is strictly required for the newly generated vasculature. Interfering in this pathological cell–cell communication between cancer cells and the nearby noncancer cells, such as targeting VEGFR, has become a promising strategy for treating human malignancies, including NPC. In general, the growing cancer cells actively release VEGF within the hypoxic microenvironment or upon stimulation of external proliferative signals such as EGF. Herein, we showed that EBV infection promoted EGF-stimulated VEGF production in NPC cells while boosting
EGF-evoked Ca\textsuperscript{2+} responses via SOCE (Figures 2A and 3A and B). Thus, we hypothesized that the amplified Ca\textsuperscript{2+} signaling that regulates cell exocytosis was responsible for the enhanced VEGF release from the EBV-infected NPC cells.\textsuperscript{26} Indeed, 2-APB, a pharmacological inhibitor of SOCE, effectively decreased the Ca\textsuperscript{2+} influx via SOCE without obviously affecting ER-released Ca\textsuperscript{2+} (Figure 4A and B) while reducing EGF-stimulated VEGF production in a dose-dependent manner (Figure 4C). Our results therefore strongly suggested that EBV infection promotes tumor angiogenesis by amplifying cytosolic Ca\textsuperscript{2+} signaling via SOCE, which is responsible for the regulation of VEGF secretion. Hence, effective reduction of the Ca\textsuperscript{2+} signaling could serve as a means to antagonize the EBV-promoted angiogenesis. To test this possibility, we further performed endothelial tube formation assays to elucidate the effect of 2-APB on angiogenesis in vitro. We found that 2-APB significantly inhibited EBV-promoted endothelial tube formation (Figures 2B and 4D).

Abnormal neovasculature formation is considered a hallmark of human cancers.\textsuperscript{27} The aberrantly generated vessels not only supply the proliferative cancer cells with nutrients and oxygen but also allow for the removal of metabolites. In the present study, we compared the growth of the EBV-positive transplanted tumors with the mock-controlled EBV-negative tumors in mice. The EBV-positive xenografts grew significantly faster than the EBV-negative controls, while more intensive vessel formation was also observed (Figure 1E–H). EBV-enhanced tumor growth and angiogenesis could be clearly observed in the same individual animal (Figure 1D and G). Of note, the promotions of tumor growth and angiogenesis shown in this model were solely attributed to EBV infection, as the bias usually caused by the physiological differences between individual animals was completely eliminated. Using this in vivo model, we showed that 2-APB effectively inhibited the growth of the EBV-positive xenografts by decreasing tumor-associated angiogenesis in vivo (Figure 5C–F).

In our earlier work on various membrane Ca\textsuperscript{2+} channels, we identified Ca\textsuperscript{2+} influx via SOCE as the predominant Ca\textsuperscript{2+} signaling that regulates extracellular EGF-stimulated cell migration in NPC cells.\textsuperscript{3} In our later study, we demonstrated that EBV-encoded LMP1 promoted EGF-induced cell migration while amplifying the EGF-evoked Ca\textsuperscript{2+} responses, whereas blocking SOCE by either pharmacological inhibitor or knockdown of ORAI1, which forms the functional unit of the membrane entries allowing Ca\textsuperscript{2+} influx for SOCE, blunted the LMP1-promoted malignant profiles, such as migration/invasion, angiogenesis, permeabilization of the endothelium, extravasation from the vasculature, and distant colonization.\textsuperscript{9} Taking our earlier findings together, pharmacological blockage of the EBV-boosted Ca\textsuperscript{2+} signaling via SOCE could serve as a feasible approach to antagonize the EBV-driven malignant biological behaviors. The mouse model concurrently bearing EBV-positive and EBV-negative xenografts is a powerful way to clarify the underlying mechanism through which EBV infection actively contributes to NPC development and is ideal for the in vivo screening of potential pharmacological targets and the verification of candidate antitumor drugs.

**Acknowledgments**

This work was supported by the National Natural Science Foundation of China (numbers 81560438 and 81602390), Guangxi Natural Science Foundation (numbers 2016GXNSFCB380003 and 2015GXNSFCA139014), a grant from the Key Laboratory of Ministry of Education, Early Stage Prevention and Control of Regional High-Incidence Cancer in Guangxi (number GJK201601), and a grant from Guangxi Medical University Training Program for Distinguished Young Scholars.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


